Skip to main content
. 2012 Jun 27;14(4):677–687. doi: 10.1208/s12248-012-9383-0

Fig. 3.

Fig. 3

Comparison of AUC for a nanosuspension and a micronized API suspension of a BCS II development candidate (Merck compound B) in rhesus monkeys. The nanosuspension resulted in improved exposures compared to the micronized suspension in a wide dose range, although at doses above 200 mg/kg no further gains in exposure were observed